Skip to main content
. Author manuscript; available in PMC: 2022 Sep 19.
Published in final edited form as: Mol Cancer Ther. 2021 Feb 3;20(4):665–675. doi: 10.1158/1535-7163.MCT-20-0386

Figure 2.

Figure 2.

High IGFBP2 expression is associated with an aggressive phenotype in MTC. A) TT cells were stably transduced with lentiviral shRNA vectors targeting IGFBP2 (sh1 and sh2) or non-target shRNA, and knockdown efficiency was determined by western blot analysis. B) IGFBP2 knockdown decreased the survival of MTC cells. The cell viability of two stable shRNA-IGFBP2 clones was analyzed by MTT assay. Data are representative of three independent experiments: error bars, ±SD (n=3) OD, optical density. C) IGFBP2 knockdown decreased the migration of MTC cells. Data are representative of three independent experiments. Error bars, ±SD (n=3). D) Representative immunohistochemical analysis of IGFBP2 in primary MTC tumors (n=52). Magnification, 20x. E) Association of high IGFBP2 expression with high tumor category (n=52). F) Association of high IGFBP2 expression with metastasis of MTC (n=52). G) High IGFBP2 expression is associated with poor overall survival. Kaplan-Meier survival analysis of 52 MTC primary tumors (P=0.0004, log-rank test). *P<0.05, ***P<0.001,****P<0.0001.